Moderna is asking for full FDA approval for the COVID vaccine – will it move the needle of vaccine skepticism?


The proportion of Americans who want to “wait and see” before being vaccinated is declining, according to surveys by the Kaiser Family Foundation.

Nearly six months later Moderna received emergency use approval from the Food and Drug Administration for the COVID-19 vaccine, the company said Tuesday. now seeks full FDA approval for a shot delivered 124 million times in America.

The drug manufacturer has partnered with Pfizer-BioNTech announced last month they seek full approval of their COVID-19 vaccine.

Is full FDA approval the vote of confidence that many reluctant Americans have to look at before they can shoot?

Time will tell, but even a new poll suggests it’s possible: 32% of unaccompanied adults told pollsters that full FDA approval could make their shots, in line with the most recent round of voting from the Kaiser Family Foundation on public ethics. about COVID-19 vaccines.

The latest edition of the survey was released on Friday, May 28. The poll found that 62% of adults said they had been vaccinated or were planning to be vaccinated, up from 56% in April.

On Tuesday, 51.7% of the American adult population was completely vaccinated and 62.8% received at least one dose, according to DATA from the U.S. Centers for Disease Control and Prevention.

32% of unaccompanied adults say full FDA approval could make them more inclined to be vaccinated, according to a May poll.

There are ongoing challenges to vaccine skepticism. The point of the case: 13% of people say they will never be vaccinated, which “significantly hasn’t changed in the past several months,” according to a new poll by the Kaiser Family Foundation.

As for full FDA approval, “I don’t think it has made a huge impact,” said Brian Castrucci, president and CEO of the de Beaumont Foundation, a foundation that focuses on public health issues. and public opinion about the vaccine.

(Castrucci spoke to MarketWatch in May, following Pfizer-BioNTech’s announcement that it was seeking full FDA approval.)

However, he added, any FDA approval raises a concern he often hears from focus groups: that vaccines allegedly have not been tested and introduced to the public with little scrutiny. “It’s going to be less of an arrow of nervous anxiety,” he said.

“There are few people who will be convinced to get it if it is approved by the FDA,” Liz Hamel, vice president and director of public opinion and research at the Kaiser Family Foundation, said last month before the foundation’s release at most new. election

The foundation survey was the latest in an ongoing public ethics vote on the vaccine that asked an open -ended question of people who said they were open to getting it, but had not yet scheduled an appointment.

Meanwhile, the number of people with a “wait and see” mindset on the vaccine is dwindling, according to the Kaiser Family Foundation ongoing tracker of public behavior. 12% of people had a “wait and see” approach in May, compared to 15% in April, down from 39% in December.

About 44% of people in this demographic say they would be exempt from vaccination with a full FDA approval, the poll showed.

The question is how many more people, at this point, are open to getting the shot at some point in the future.

It gets to the point that no single line of argument, strategy or event can heal skeptics, according to experts.

“The‘ hard no ’group has been consistent since December,” Hamel said.

The Pfizer-BioNTech vaccine, Moderna vaccine and Johnson & Johnson vaccine were all used in public use after the FDA granted emergency use permission. Last month, the FDA said 12- to 15-year-olds may receive Pfizer-BioNTech vaccine.

The process of authorizing emergency use is no more stringent than full approval, according to a blog post by Dr. Malia Jones, an associate health geography scientist working at the University of Wisconsin-Madison Applied Population Laboratory. “It’s done based on good scientific data. It’s not as big of a dataset as it is to be submitted for a full FDA approval,” he said. WROTE.

Diversity is important in other aspects of the vaccination debate. Allegations challenged employers requiring workers to be vaccinated everyone chose their legal arguments the fact that COVID-19 vaccines are available to the public by authorizing emergency use. Cases are pending.

Whenever full FDA approval comes, Castrucci sees a potential argument for skeptics that “well, we see that’s what the government says it’s safe.” That’s the challenge when it comes to questioning the vaccine, he said. “There are groups of people who are just trying to spread misinformation and unreasonable reasons to undermine reliance on vaccines to prolong the pandemic.”

It gets to the point that no single line of argument, strategy or event can provoke skeptical people, like Castrucci and Hamel.

Castrucci said it’s important to “stop blaming and embarrassing” and make sure reluctant Americans hear about the importance of vaccination from credible messengers. He said he fell into five ‘P’s’ – doctors, pharmacists, parents, peers and pastors.

“The more people get vaccinated, the more we’re going to get to the point where we can’t be shaken,” he said. However, he added, “it’s not a sprint, it’s a marathon.”

Some people may go on for reasons unrelated to skeptical science, Hamel said.

Of people who were concerned about vaccination in the April edition of the Kaiser poll, 48% said they were worried about the effects that could force them to quit work. In the May edition of the poll, 21% of unskilled working adults said they would rather get their shots if their boss offered them paid time.

(CDC note common side effects may include pain, fatigue and tremors, especially after the second shot.)

The vaccine is free for everyone, but in the April poll 32% still said they were worried about out -of -pocket costs. People who express these financial concerns are always Black and Hispanic, according to Hamel. Like him and the others that’s an access problem, instead of asking.

When it comes to getting people to vaccination areas now, Hamel said, “we’re at the stage where most interventions work at a smaller percentage … Now is the time that every tool should come out of the toolbox . “

This story was originally published on May 7 and updated on June 2.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *